MedTrace Logo

Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity

NCT01044810 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 559

Last updated 2011-03-15

No results posted yet for this study

Summary

The primary objective of this study is to compare the effectiveness of EFV-based regimens in HIV-1-infected patients who; (1) were previously allergic to NVP and stopped all ARV simultaneously; (2) were previously allergic to NVP and continued the other NRTIs for a period of time, i.e. "staggered interruption"; and (3) started EFV-based regimens as an initial regimen (as controlled group).

Conditions

  • Treatment Failure, HIV or AIDS
  • CD4 Cell Counts

Interventions

DRUG

Efavirenz-based regimens

Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.

Sponsors & Collaborators

  • Thai Red Cross AIDS Research Centre

    collaborator OTHER

  • Clinical Research Collaborative Network

    collaborator NETWORK

  • Bamrasnaradura Infectious Diseases Institute

    lead OTHER_GOV

Principal Investigators

  • Krittaecho Siripassorn, MD · Bamrasnaradura Infectious Diseases Institute

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044810 on ClinicalTrials.gov